8-K: 4DMT Expands Wet AMD Trial Enrollment for Global Reach

4D Molecular Therapeutics announced protocol amendments to increase patient enrollment in its 4D-150 wet AMD Phase 3 trials to support global regulatory submissions.

Summary

• 4D Molecular Therapeutics, Inc. (FDMT) intends to implement protocol amendments to its 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials for 4D-150 in wet Age-related Macular Degeneration (AMD).
• The target enrollment for each trial will increase from 400 to 480 patients, totaling 960 patients across both trials.
• This increase is designed to provide approximately 90% power with a noninferiority margin of approximately 4 letters for regulatory agencies outside of FDA jurisdiction, such as the Japan Pharmaceuticals and Medical Devices Agency (PMDA) and European Medicines Agency (EMA).
• The original trial design provided >90% power for a primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks with a margin of 4.5 letters, in accordance with U.S. Food and Drug Administration (FDA) guidance.
• The amendments support planned global regulatory submissions for 4D-150, including those by the recently announced partner, Otsuka Pharmaceutical Co., Ltd., in the Asia-Pacific region.
• The decision was driven by an evolving view of the global commercial opportunity for 4D-150.
• As of December 10, 2025, 4FRONT-1 has 300 patients randomized or approved to randomize.
• 4FRONT-2 ex-U.S. site activation pace is consistent with plans, with first patients screened in Europe and sites active in the Asia-Pacific region.
• The company anticipates no impact of these amendments on previously guided enrollment projections for the 4FRONT Trials or on its previously guided financial runway into H2 2028.
• Enrollment for 4FRONT-1 is still expected to complete in Q1 2026, with topline data disclosure in H1 2027.
• Enrollment for 4FRONT-2 is still expected to complete in H2 2026, with topline data disclosure in H2 2027.

Sentiment

Score: 7

Explanation: The announcement reflects a positive strategic move to expand the global market opportunity for 4D-150 without impacting existing timelines or financial runway. It demonstrates proactive planning for international regulatory submissions and leverages a key partnership. While not a clinical data readout, it strengthens the long-term commercial potential.

Positives

• Strategic expansion of clinical trials to align with global regulatory standards (e.g., PMDA, EMA) broadens the potential market for 4D-150.
• The increased enrollment supports planned global regulatory submissions, leveraging the partnership with Otsuka Pharmaceutical Co., Ltd. for the Asia-Pacific region.
• Despite increasing trial size, the company anticipates no impact on previously guided enrollment projections or its financial runway into H2 2028, indicating efficient planning and resource management.
• Maintaining existing timelines for enrollment completion (Q1 2026 for 4FRONT-1, H2 2026 for 4FRONT-2) and topline data disclosure (H1 2027 for 4FRONT-1, H2 2027 for 4FRONT-2) is a positive sign of operational execution.

Risks

• General risks and uncertainties inherent in clinical development and regulatory pathways, which could cause actual results and events to differ materially from anticipated outcomes.
• Risks detailed in the Company's most recent Quarterly Report on Form 10-Q and subsequent SEC filings.

Future Outlook

The company's future outlook is focused on advancing 4D-150 through Phase 3 clinical trials with an expanded global regulatory strategy. This includes completing enrollment for both 4FRONT-1 and 4FRONT-2 trials by Q1 2026 and H2 2026, respectively, and disclosing topline data in H1 2027 and H2 2027. The amendments are a proactive step to support global regulatory submissions and capitalize on the evolving global commercial opportunity for 4D-150.

Management Comments

• The company's evolving view of the global commercial opportunity for 4D-150 drove the decision to increase target enrollment for global regulatory submissions.
• Management anticipates no impact of the amendments on previously guided enrollment projections for the 4FRONT Trials.
• Management anticipates no impact on the company's previously guided financial runway into H2 2028.

Industry Context

This announcement positions 4D Molecular Therapeutics to compete more broadly in the global wet AMD market, a significant therapeutic area with high unmet needs. By aligning trial design with international regulatory standards, the company aims to facilitate market access beyond the U.S., particularly in Asia-Pacific through its partnership with Otsuka Pharmaceutical. The noninferiority comparison to aflibercept, a leading treatment, highlights the competitive landscape and the company's strategy to demonstrate comparable efficacy for its gene therapy candidate.

Comparison to Industry Standards

• The trials are designed to demonstrate noninferiority of 4D-150 against aflibercept 2mg Q8 weeks, a standard treatment in wet AMD.
• The noninferiority margin for FDA guidance was 4.5 letters, while the amended protocol targets approximately 4 letters for ex-U.S. agencies like PMDA and EMA, indicating a slightly stricter standard for global market entry.
• The expansion of trial size to 480 patients per trial (from 400) is a common strategy in late-stage clinical development to enhance statistical power for broader regulatory acceptance and to support global market applications, similar to practices seen in other large pharmaceutical and biotech companies pursuing international approvals.

Stakeholder Impact

• Shareholders: Potential for increased market opportunity and long-term value if 4D-150 achieves global approvals, but also increased complexity in trial management.
• Patients: Expanded trial enrollment may offer more opportunities for participation in the clinical study.
• Regulatory Authorities: The company is proactively addressing the specific requirements of various global regulatory bodies (FDA, PMDA, EMA).
• Partners (Otsuka Pharmaceutical Co., Ltd.): The amendments directly support their planned submissions in the Asia-Pacific region, reinforcing the partnership's strategic alignment.

Next Steps

• Complete enrollment of 4FRONT-1 in Q1 2026.
• Complete enrollment of 4FRONT-2 in H2 2026.
• Disclose topline data for 4FRONT-1 in H1 2027.
• Disclose topline data for 4FRONT-2 in H2 2027.
• Pursue global regulatory submissions for 4D-150, including with Otsuka Pharmaceutical Co., Ltd. in the Asia-Pacific region.

Key Dates

Recommendation

The strategic decision to increase trial enrollment for global regulatory alignment is a positive long-term move, indicating confidence in 4D-150's potential and expanding market opportunity. However, it does not provide new clinical data or immediate financial upside, thus maintaining a 'hold' stance until further clinical milestones or financial updates. The execution of these expanded trials and subsequent regulatory success will be key determinants of future value.

Keywords

4D Molecular Therapeutics, FDMT, 4D-150, wet AMD, clinical trials, Phase 3, gene therapy, ophthalmology, Otsuka Pharmaceutical, FDA, EMA, PMDA, regulatory submissions